Orthogonal Temperature-Related Intensity Change and Time-Resolved Förster Resonance Energy Transfer High-Throughput Screening Platform for the Discovery of SLIT2 Binders

Materials and reagents

Biological materials

Critical note: Glycosylated extracellular proteins like SLIT2 and ROBO1 are prone to aggregation and loss of activity when repeatedly thawed. Prepare small aliquots (20–30 μL) to minimize freeze-thaw events. Before each use, centrifuge briefly (10,000× g, 1 min) to remove any precipitate.

Reagents for TRIC/MST

Reagents for TR-FRET

Solutions

1. Screening buffer (TRIC/MST) (see Recipes)

2. TR-FRET assay buffer (see Recipes)

Recipes

1. Screening buffer (TRIC/MST)

Screening buffer can be prepared using either (i) 1× PBS (pH 7.4) or (ii) 50 mM HEPES pH 7.4 supplemented with 150 mM NaCl. In both cases, add 0.005% Tween-20. Filter (0.22 μm) and prepare fresh daily. Keep on ice during use.

Note: PBS and HEPES-based buffers were both compatible with this workflow. Maintaining a constant 2% DMSO across all wells reduces viscosity and matrix-driven variability in TRIC. Use minimal detergent (≤0.005% Tween-20) to limit nonspecific adsorption while preserving TRIC sensitivity. If changes are needed for solubility or sticking, adjust one parameter at a time and re-verify baseline stability, signal direction, and replicate variability before screening.

2. TR-FRET assay buffer

Use the supplied PPI Tb detection buffer without further modification. Equilibrate to room temperature before use to prevent condensation on plates.

Laboratory supplies

Equipment

Software and datasets

Procedure

Part I: TRIC primary screening (Dianthus)

The goal here is to identify small molecules that bind recombinant human SLIT2-His using temperature-related intensity change (TRIC). TRIC measures micro-environmental fluorescence changes in labeled proteins under IR-induced temperature gradients. Binding of small molecules alters local hydration and fluorescence intensity, providing a solution-based readout of molecular interaction.

A. Labeling of target protein (per manufacturer; scalable)

Note: This is performed as recommended by the manufacturer (NanoTemper) with minor adaptations. Volumes below are example working volumes and must be scaled to match plate count (see step A9).

1. Prepare 1× PBS-T. Add 8.0 mL of ddH₂O to the vial containing 5× PBS-T to obtain 1× PBS-T. Mix gently.

2. Make a 5 μM dye stock in PBS-T. Suspend the dye in 25 μL of 1× PBS-T (5 μM dye).

3. Make a 100 nM dye solution. Mix 2 μL of 5 μM dye with 98 μL of 1× PBS-T (100 μL at 100 nM dye).

4. Adjust protein to 200 nM. Prepare 100 μL of hSLIT2-His at 200 nM in 1× PBS-T.

5. Label (1:1 volume). Combine 90 μL of protein (200 nM) with 90 μL of dye (100 nM) (180 μL labeled mixture). Resulting concentrations in the mix: protein 100 nM, dye 50 nM.

6. Incubate for 30 min at room temperature, protected from light.

7. Clarify by centrifuging at 15,000× g for 10 min at 4 °C. Transfer the supernatant to a fresh, low-bind tube.

8. Ready-to-use 2× protein working solution: The supernatant is the 2× labeled-protein stock for TRIC (protein 100 nM, dye 50 nM in 1× PBS-T). In section C, you will add 10 μL of this 2× protein to 10 μL of 2× compound per well (total 20 μL), yielding a final 50 nM SLIT2 and 100 μM compound in-well. DMSO is supplied from the 2× compound side, so the in-well final DMSO is 2% without adding DMSO during labeling.

9. Scaling guidance (for any plate size):

a. Estimate total wells (including controls) and add 10%–15% overage.

b. Required 2× protein volume = (wells × 10 μL) × 1.1–1.15.

c. If more volume is needed, proportionally scale steps A3–7 to keep the protein:dye ratio at 100:50 nM in the final labeled mix.

d. Use low-bind plastics, keep on ice, and use within 24 h. Freezing labeled protein resulted in a weaker signal in our hands (data not shown); therefore, prepare labeled protein fresh for each experiment.

B. Compound plate preparation

1. Thaw source library plates (10 mM stocks in 100% DMSO) at room temperature for ≥30 min before opening. Thaw each source plate once to prepare intermediate plates; reseal promptly to minimize evaporation and repeat freeze-thaw of the source plate.

2. Prepare 2× intermediate plates by diluting compounds into screening buffer to 200 μM (2×). Intermediate plates can be reused if necessary, but repeated freeze-thaw cycles increase variability; when possible, prepare fresh and use the same day.

3. Mix using a liquid handler or electronic multichannel pipettor to minimize variability (e.g., Integra VIAFLO 96 or equivalent).

C. TRIC assay assembly (Dianthus Platform) (10 μL + 10 μL, 2× reagents)

1. Predispense compounds: Add 10 μL of 2× compound solution (200 μM) to each well of a 384-well barcoded Dianthus plate.

2. Add protein: Add 10 μL of 2× labeled SLIT2 (prepared so that the final SLIT2 is 50 nM) to each well.

3. Final per-well conditions (20 μL total volume): SLIT2, 50 nM; Compound, 100 μM; DMSO: 2%; Buffer, 50 mM HEPES pH 7.4, 150 mM NaCl, 0.005% Tween-20.

4. Controls (same volumes/conditions): Negative (vehicle), 2% DMSO only; positive, 100 μM bexarotene; blank, buffer only (no protein).

5. Seal and incubate for 20 min at room temperature (22–25 °C), protected from light.

D. TRIC data acquisition

1. Read on NanoTemper Dianthus with IR-laser power 100%, MST power medium, readout Fnorm, temperature 25–27 °C. Typical acquisition time is ~15–30 min per 384-well plate, depending on instrument settings and plate load.

2. Export Fnorm values using DI.Control and review instrument QC flags (aggregation, quenching, autofluorescence).

E. Autofluorescence, quenching, and aggregation filtering

1. Baseline screen (pre-heating scan): Identify wells outside ± 1 SD of the plate’s reference mean. High baseline → likely autofluorescence; low baseline → likely quenching/bleaching.

2. Exclude anomalies: Remove wells flagged by DI.Control for aggregation or scan artifacts.

3. Proceed with clean wells only. (Typically, ~90%–95% of screened compounds pass QC after this step.)

Note: These filters ensure TRIC intensity changes reflect true binding rather than photophysical or colloidal artifacts.

F. Hit selection

1. Exclude wells flagged by instrument quality control for autofluorescence, quenching, or other signal interference.

2. Using the remaining wells, compute the vehicle control reference distribution for Fnorm on the same plate (mean and standard deviation).

3. Define preliminary hits as compounds whose Fnorm deviates from the vehicle control mean by more than three standard deviations (absolute deviation threshold).

4. Advance clean preliminary hits to multi-point dose response binding measurements and/or orthogonal validation assays.

G. Binding affinity determination (Monolith X MST/TRIC)

1. Prepare dilution series: For each compound, make a 24-point 2-fold serial dilution starting from 400 μM (or 300 μM if solubility-limited) in screening buffer, maintaining 2% DMSO.

2. Mixing/incubation: Combine equal volumes of compound dilution and 100 nM labeled SLIT2 to yield 50 nM final protein; incubate for 20 min at RT, protected from light, and centrifuge for 5 s to clear bubbles.

3. Measurement: Load 10 μL per capillary/well; acquire triplicates at laser 100%, MST medium, and 10 s acquisition.

Part II: TR-FRET inhibition assay (384-well low-volume)

The goal here is to quantify the inhibition of SLIT2–ROBO1 interaction by confirmed TRIC hits. Energy transfer occurs between Tb³⁺-donor (anti-human IgG-Tb recognizing ROBO1-Fc) and d2-acceptor (anti-His recognizing SLIT2-His). Disruption of the SLIT2–ROBO1 complex decreases the 665/620 nm emission ratio.

1. Plate layout: Use white, low-volume 384-well plates (Figure 3). Allocate triplicates for vehicle (0% inhibition) and positive control (100% inhibition; no SLIT2).

Figure 3. 384-well assay plate map. Schematic layout showing the placement of test compounds and assay controls. Test compounds (blue) are dispensed in rows B–D, columns 4–21. Vehicle controls (red) and positive controls (green) are positioned on both sides of the compound block (columns 2–3 and 22–23 in rows B–D) to provide within-plate reference points for data processing and QC. All remaining wells are left empty or unused (pink). A single well is shown in light blue as a plate map marker (not used for test compounds or controls).

2. Reagent preparation: Dilute each reagent to the following working concentrations in TR-FRET buffer (Table 1):

Table 1. List of reagents and working concentrations for the TR-FRET assay

3. Dispensing order (per well):

a. Add 2 μL of 10× compound (in 20% DMSO).

b. Add 2 μL of 20% DMSO to vehicle and positive control wells.

c. Add 4 μL of SLIT2-6His (5× stock).

d. Add 4 μL of ROBO1-Fc (5× stock).

e. Add 5 μL of anti-6His d2 (4×).

f. Add 5 μL of anti-Human IgG-Tb (4×).

g. Mix by pipetting 20× using an electronic pipettor.

h. Seal the plate and incubate for 1 h at RT on a plate shaker (300 rpm).

4. Detection: Read on Tecan Infinite M1000 Pro with the following parameters: excitation, 340 nm; emission, 620 nm (donor) and 665 nm (acceptor); delay, 60 μs; integration, 400 μs. Calculate TR-FRET ratio = (665/620) × 10⁴ [9]. Multiplication by 10,000 is a conventional scaling factor used in HTRF readouts to keep values in a convenient numeric range; it does not affect curve fitting or relative comparisons.

5. Data interpretation: Compute % inhibition per well:

$$\text{\%Inhibition}=100\times \left[1-\frac{(R_{\text{sample}}-R_{\text{positive}})}{(R_{\text{vehicle}}-R_{\text{positive}})}\right]$$

where R = 665/620 ratio.

a. Fit dose-response curves with a four-parameter logistic model to obtain IC₅₀ values.

b. Typical I_max for partial inhibitors such as bexarotene ≈ 40%.

A representative example of the screening workflow described herein can be found in Table 2.

Table 2. A representative outcome from the screening workflow

*Refer to the plate map in Figure 3. Add reagent to microplate using single-channel pipettor.

Data analysis

Accurate and transparent analysis of TRIC and TR-FRET data is essential for distinguishing true binders and inhibitors from optical or thermal artifacts. The following subsections describe standardized analysis workflows, recommended software settings, and common error sources.

A. TRIC screening and hit identification

1. Data extraction

a. Open raw DI.Control output files (.csv or .xlsx) containing Fnorm values per well.

b. Remove any wells flagged by DI.Control for autofluorescence, quenching, aggregation, or other signal interference before hit calling.

c. For each plate, compute the mean (μ) and standard deviation (σ) of the vehicle (DMSO) control wells using the remaining QC clean wells.

2. Hit thresholding

a. Define preliminary hits based on the magnitude of the Fnorm deviation from the vehicle control distribution. Specifically, classify a compound as a preliminary hit if its Fnorm value deviates from the vehicle control mean by at least three standard deviations (absolute deviation threshold):

|Fnormwell − μDMSO| ≥ 3Σdmso

b. This 3× SD threshold provides a stringent cutoff for identifying outliers relative to vehicle controls while avoiding reliance on Z-score calculations.

c. Visualize the distribution of Fnorm values and preliminary hits in Prism or Excel using scatterplots or distribution plots (for example, per plate scatter with control bounds at μ ± 3σ).

3. Plate performance

a. Assess plate quality by checking that vehicle controls are stable and that replicate control wells show low variability (σDMSO) and a consistent baseline Fnorm. If a positive control is included on the plate, confirm that it produces a consistent shift in Fnorm relative to vehicle controls.

• If control variability is high or baseline drift is observed, repeat the plate and confirm buffer composition, DMSO consistency, temperature equilibration, and compound handling.

Critical: False positives can appear as both increases and decreases in Fnorm. Evaluate the consistency of the direction and magnitude of the Fnorm shift across replicate measurements before moving to multi-point dose response testing.

B. Binding affinity (Kd) determination: Monolith X

1. Data normalization

a. Import triplicate Fnorm values into GraphPad Prism.

b. Subtract baseline signal (compound-free control).

c. (Optional) Normalize to percent binding using:

$$\text{Fraction bound}=\frac{F\text{norm}{}_{\text{obs}}-F_{\text{min}}}{F_{\text{max}}-F_{\text{min}}}$$

2. Curve fitting

a. Use nonlinear regression with a one-site binding model:

$$Y=B_{\text{max}}\times \frac{\left[L\right]}{K_d+\left[L\right]}$$

where [L] is ligand concentration.

b. Report mean Kd ± SD from ≥3 independent experiments.

c. Display replicate traces with individual data points, not only fitted lines.

3. Acceptance criteria:

a. R² ≥ 0.90 for each fit.

b. Triplicate CV ≤ 10%.

c. Consistent slope direction (monotonic).

d. Deviations or plateau shifts indicate compound aggregation or labeling instability.

Troubleshooting tip: If the binding curve shows two distinct transitions, the compound likely aggregates above ~100 μM. Re-run using a lower concentration range or add 0.01% Triton X-100 to the buffer to test for colloidal behavior.

C. TR-FRET inhibition and IC₅₀ determination

1. Ratio calculation. For each well, compute:

$$R=\left(\frac{I_{665}}{I_{620}}\right)\times {10}^4$$

where I₆₆₅ and I₆₂₀ are background-subtracted emission intensities at 665 and 620 nm, respectively.

2. Normalization and percent inhibition:

$$\text{\%Inhibition}=100\times \left[1-\frac{(R_{\text{sample}}-R_{\text{positive}})}{(R_{\text{vehicle}}-R_{\text{positive}})}\right]$$

R_vehicle: SLIT2 + ROBO1 + DMSO (0% inhibition)

R_positive: ROBO1 + detection reagents only (100% inhibition reference)

3. Dose-response fitting

a. Import normalized inhibition data into Prism.

b. Apply a four-parameter logistic (4PL) fit:

$$Y=\mathrm{Bottom}+\frac{\mathrm{Top}-\mathrm{Bottom}}{1+{10}^{\left(\mathrm{LogIC}{}_{50}-X\right)\times \mathrm{HillSlope}}}$$

c. Use triplicates per concentration and weight by inverse variance if necessary.

d. Extract IC₅₀ and Hill slope.

4. Acceptance and reproducibility: Perform three independent runs to ensure reproducibility.

Critical: Partial inhibitors (I_max < 50%) are biologically meaningful for extracellular PPIs, which often lack deep binding pockets. Report both IC₅₀ and I_max to contextualize the mechanism (allosteric or steric).

D. Statistical considerations

1. Perform three independent biological replicates (separate protein preps).

2. Present data as mean ± SD or mean ± SEM as specified.

3. Apply unpaired two-tailed t-tests or one-way ANOVA for comparison of multiple conditions.

4. Report exact n values, replicates, and source data in supplementary tables.

E. Example results

Refer to Table 3 for a representative dataset for bexarotene as a SLIT2-binder and SLIT2/ROBO1 inhibitor.

Table 3. Example results (representative dataset)

Visualization: Plot dose-response in Prism with log[compound] on the x-axis and normalized % inhibition on the y-axis. Overlay triplicates and include 95% CI bands to convey fit confidence.

F. Quality control and validation

1. Confirm that vehicle and positive controls yield consistent TR-FRET ratio separation across ≥3 plates.

2. Verify no systematic drift in TRIC Fnorm baseline across screening batches.

3. Document all outlier removal criteria transparently in supplementary data.

4. Recommended practice: Re-test 10% of primary TRIC hits in an independent run before progressing to TR-FRET validation. This step detects stochastic or plate-specific anomalies.

Validation of protocol

The validation metrics reported here are derived from the application of this exact workflow to the SLIT2–ROBO1 extracellular domain pair using bexarotene as a representative positive control, as described in [1]. In that study, the primary TRIC screen was used to identify and triage candidate binders (including exclusion of artifacts using the same baseline and quality control logic described in this protocol), followed by confirmatory multi-point TRIC and/or MST measurements on Monolith X to estimate binding affinity (Kd). Functional follow-up was performed using the TR-FRET inhibition assay described here, generating concentration response curves and corresponding inhibition metrics (for example, IC₅₀ or relative inhibition) under the same assay format. Together, these data provide empirical validation that the integrated TRIC plus TR-FRET pipeline produces reproducible binding and functional readouts for an extracellular protein–protein interaction under the conditions described in this protocol (see [1] and Figure 4 for the representative curves and summary metrics).

Figure 4. Representative temperature-related intensity change (TRIC)/microscale thermophoresis (MST) binding and time-resolved Förster resonance energy transfer (TR-FRET) inhibition curves for bexarotene in the SLIT2–ROBO1 model system. (A) Representative TRIC/MST dose response curve showing binding of bexarotene to fluorescently labeled SLIT2, plotted as normalized fluorescence (Fnorm) versus compound concentration (M, log scale). The fitted binding model yields an apparent Kd = 2.62 ± 0.36 μM (as shown). (B) Representative TR-FRET concentration response curve showing inhibition of the SLIT2–ROBO1 extracellular interaction by bexarotene, plotted as % inhibition versus compound concentration (M, log scale). The fitted curve yields an apparent EC50 = 77.27 ± 17.32 μM (as shown). Data points are shown with error bars reflecting variability across replicate measurements.

1. Inter-assay reproducibility

a. TRIC primary screen: Three independent 384-well plates on different days, using separate SLIT2-His labeling batches.

b. Monolith X affinity determination: Replicates: n = 3 biological repeats × 3 technical replicates each. Mean Kd (bexarotene-SLIT2): 2.62 ± 0.3 μM.

c. Criterion for acceptance: RSD ≤ 15% across days for the same protein batch and compound.

2. TR-FRET orthogonal validation

Concentration-response: Bexarotene displayed IC₅₀ = 77 ± 17 μM and I_max ≈ 40, consistent with partial inhibition.

3. Intra-plate uniformity and edge effects

Analyze column- and row-wise mean signals from 384-well TR-FRET plates. Mitigation: Pre-equilibrating plates at RT and using adhesive seals minimized evaporation artifacts.

4. Long-term robustness

a. Re-tested labeled SLIT2 stored at 4 °C for 2 days: TRIC signal retained less than 50% intensity.

b. TR-FRET reagents (donor/acceptor antibodies) remained stable for >3 months at 4 °C when protected from light.

General notes and troubleshooting

General notes

1. Consistency of DMSO concentration: Maintain a constant 2% DMSO across all wells.

2. Protein quality and storage

a. SLIT2 and ROBO1 are large, glycosylated extracellular proteins that can aggregate after freeze-thaw cycles.

b. Prepare small aliquots (20–30 μL) and store at -80 °C.

c. Thaw only once, on ice, and centrifuge briefly to remove insoluble material.

d. If aggregation is suspected (cloudy solution, loss of signal), filter through 0.22 μm spin filters.

3. Light protection

a. RED-tris-NTA and d2 acceptor dyes are light-sensitive.

b. Work under dim light, cover tubes with foil, and minimize exposure during labeling and incubation.

c. Faded signal or rising baseline fluorescence often indicates photobleaching.

4. Plate handling

a. Use pre-equilibrated plates (25–27 °C) to avoid condensation that affects optical paths.

b. Always seal plates immediately after dispensing reagents to prevent edge evaporation.

c. Do not reuse plates; residual fluorophores can cause carry-over.

5. Instrument equilibration

a. Before each TRIC run, allow Dianthus and Monolith X instruments to equilibrate for at least 30 min.

b. Sudden temperature changes introduce baseline drift in Fnorm values.

c. For TR-FRET, ensure plate reader optics are clean and calibrated with terbium and rhodamine standards monthly.

6. Mixing uniformity

a. Inconsistent mixing is a major cause of variable FRET ratios.

b. Mix every well exactly the same number of times (e.g., 20× with an electronic pipettor).

c. Avoid vortexing microplates; it produces bubbles that scatter excitation light.

7. Buffer composition

a. TRIC and TR-FRET signals are sensitive to ionic strength and detergent.

b. Keep Tween-20 ≤ 0.005%; higher levels suppress temperature-induced fluorescence changes.

c. Avoid phosphate buffers; phosphate quenches terbium emission.

8. Replicate strategy

a. Use (at least) triplicates per concentration for dose-response curves.

b. For screening plates, distribute control wells evenly across the plate (not just corners) to detect positional bias.

Troubleshooting (Table 4)

Table 4. Troubleshooting

Good laboratory practices for TRIC/TR-FRET:

1. Always run a calibration plate weekly using donor/acceptor standards to monitor instrument drift.

2. Maintain a master log documenting labeling yield, fluorescence intensity, Z′-factors, and operator notes.

3. For publications, include raw Fnorm and ratio datasets in the supplementary material for transparency.

4. Re-validate assay performance whenever switching to a new protein batch or library source.

5. Avoid prolonged exposure of labeled proteins to plastic tips or reservoirs; use low-binding consumables.

Troubleshooting flowchart:

1. No TRIC signal: Check laser alignment, verify dye emission, and confirm protein concentration.

2. High false positives: Examine baseline fluorescence, filter ±1 SD, and re-screen subset.

3. No FRET window: Confirm donor/acceptor stocks, run control plate, and adjust protein ratio (SLIT2:ROBO1 = 5:1).

4. Low reproducibility: Review pipetting consistency, replace seals, and re-measure with fresh buffer.

Critical notes and troubleshooting

• Labeling stability: Keep RED-tris-NTA and labeled SLIT2 protected from light. Fluorophore degradation or oxidation can cause baseline drift.

• DMSO consistency: Maintain 2% final DMSO in all wells. We evaluated DMSO from 0% to 10% and found that <2% or >5% increased assay noise under these conditions (data not shown).

• Plate temperature: For TR-FRET, equilibrate plates to room temperature before reading. Uneven temperature gradients across wells can skew the 665/620 ratio.

• Pipetting accuracy: When dispensing <10 μL volumes, pre-wet tips to prevent volume loss from surface tension.

• Protein quality check: If TRIC baseline variance exceeds 1 SD across the plate, prepare a fresh batch of labeled protein and confirm spectral properties (excitation/emission = 650/670 nm).

Troubleshooting and notes for TR-FRET inhibition assay

Acknowledgments

Conceptualization: M.T.G.; Methodology: N.G.V., S.A.A.; Investigation: N.G.V., S.A.A.; Formal analysis: N.G.V.; Writing–Original Draft: N.G.V., S.A.A.; Writing–Review & Editing: N.G.V., S.A.A., M.T.G.; Funding acquisition and Supervision: M.T.G.

Funding: Supported by the National Cancer Institute R01CA293456 (PI: Gabr).

We acknowledge our prior publication where parts of this protocol were described and validated [1].

Competing interests

The authors declare no conflicts of interest.

Ethical considerations

This protocol involves only recombinant proteins and does not require institutional ethics approval.

References

1. García-Vázquez, N. and Gabr, M. T. (2025). Orthogonal temperature-related intensity change (TRIC) and TR-FRET as a high-throughput screening platform for the discovery of SLIT2 binders: A proof-of-concept approach. SLAS Discov. 35: 100264. https://doi.org/10.1016/j.slasd.2025.100264
2. Abdel-Rahman, S. A. and Gabr, M. T. (2025). Optimization and development of a high-throughput TR-FRET screening assay for SLIT2/ROBO1 interaction. SLAS Discov. 34: 100240. https://doi.org/10.1016/j.slasd.2025.100240
3. Brose, K., Bland, K. S., Wang, K. H., Arnott, D., Henzel, W., Goodman, C. S., Tessier-Lavigne, M. and Kidd, T. (1999). Slit Proteins Bind Robo Receptors and Have an Evolutionarily Conserved Role in Repulsive Axon Guidance. Cell. 96(6): 795–806. https://doi.org/10.1016/s0092-8674(00)80590-5
4. Blockus, H. and Chédotal, A. (2016). Slit-Robo signaling. Development. 143(17): 3037–3044. https://doi.org/10.1242/dev.132829
5. Tong, M., Jun, T., Nie, Y., Hao, J. and Fan, D. (2019). The Role of the Slit/Robo Signaling Pathway. J Cancer. 10(12): 2694–2705. https://doi.org/10.7150/jca.31877
6. Wang, B., Xiao, Y., Ding, B. B., Zhang, N., Yuan, X. b., Gui, L., Qian, K. X., Duan, S., Chen, Z., Rao, Y., et al. (2003). Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell. 4(1): 19–29. https://doi.org/10.1016/s1535-6108(03)00164-8
7. Gara, R. K., Kumari, S., Ganju, A., Yallapu, M. M., Jaggi, M. and Chauhan, S. C. 2015). lit/Robo pathway: a promising therapeutic target for cancer. Drug Discov. 20(1): 156–164. https://doi.org/10.1016/j.drudis.2014.09.008
8. Bhosle, V. K., Mukherjee, T., Huang, Y. W., Patel, S., Pang, B. W., Liu, G. Y., Glogauer, M., Wu, J. Y., Philpott, D. J., Grinstein, S., et al. (2020). LIT2/ROBO1-signaling inhibits macropinocytosis by opposing cortical cytoskeletal remodeling. Nat Commun.11(1): 4112. https://doi.org/10.1038/s41467-020-17651-1
9. Degorce, F. (2009). HTRF: A Technology Tailored for Drug Discovery - A Review of Theoretical Aspects and Recent Applications. Curr Chem Genomics. 3(1): 22–32. https://doi.org/10.2174/1875397300903010022
10. Zhang, J. H., Chung, T. D. and Oldenburg, K. R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. SLAS Discov. 4(2): 67–73. https://doi.org/10.1177/108705719900400206
11. Seidel, S. A., Dijkman, P. M., Lea, W. A., van den Bogaart, G., Jerabek-Willemsen, M., Lazic, A., Joseph, J. S., Srinivasan, P., Baaske, P., Simeonov, A., et al. (2013). Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods. 59(3): 301–315. https://doi.org/10.1016/j.ymeth.2012.12.005
12. Schulte, C., Khayenko, V., Nordblom, N. F., Tippel, F., Peck, V., Gupta, A. J. and Maric, H. M. (2021). High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale. iScience. 24(1): 101898. https://doi.org/10.1016/j.isci.2020.101898
13. Jeridi, S., Rak, A., Gupta, A. and Soule, P. (2021). Fast Mek1 Hit Identification with TRIC Technology Correlates Well with Other Biophysical Methods. SLAS Discov. 26(8): 1014–1019. https://doi.org/10.1177/24725552211026267
14. Calvo-Barreiro, L., Upadhyay, S. and Gabr, M. T. (2025). Temperature-related intensity change (TRIC)-based high-throughput screening enables the discovery of small molecule CD28 binders. SLAS Discov. 35: 100256. https://doi.org/10.1016/j.slasd.2025.100256